Quantcast

Industry news that matters to you.  Learn more

GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic Steatohepatitis (NASH)

LabCorp, a leading global life sciences company, and GENFIT, a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, have announced the signing of a licensing agreement between GENFIT and Covance, LabCorp’s drug development business. The agreement will expand access to an innovative non-alcoholic steatohepatitis (NASH) liver diagnostic test for the clinical research market.

Quanterix Extends Oncology Footprint with Accelerated Launch of Next Gen SP-X Platform and CorPlex Validated 10-Plex

Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the much-anticipated full launch of its Simoa SP-X Imaging and Detection System, 10-Plex Simoa CorPlex Cytokine Panel, and broad menu of additional multiplex panels. The new instrument platform and highly validated CorPlex assays promise to revolutionize oncology research and drug development. The progress made since the early access program was initiated in early November 2018 with select industry leaders has validated the performance and promise of the technology, resulting in an accelerated timeline for full launch. The company is now taking orders for shipping by April 1.

Quanterix Marks Leadership in Accelerating Neurology Research with 100-Publication Milestone

Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, recently announced it has surpassed an important milestone that its technology has been highlighted in more than 100 third-party, peer-reviewed publications in neurology. Driven by increased demand for the company’s Simoa technology, which continues to prove itself as the industry standard for ultra-sensitive biomarker detection, this brings the total number of publications for the company to over 215 across neurology, oncology, cardiology, inflammation and infectious disease.

Biodesix Blood-Based Diagnostic Testing Approach To PD-L1 Detection Shows Concordance with Immunohistochemistry

Biodesix presented preliminary data evaluating a blood-based PD-L1 assay to identify patients who may benefit from cancer immunotherapies. The data were presented last week at the AACR-NCI-EORTC conference. The study was conducted in collaboration with Dr. Michael Pritchett, from FirstHealth Moore Regional Hospital, Pinehurst Medical Clinic, and Dr. Jiaxin Niu, from Banner MD Anderson Cancer Center.

Recently Identified Biomarker Could Be Valid Diagnostic Tool for Gaucher Disease, Mouse Study Suggests

Glucosylsphingosine (lyso-Gb1), a recently identified biomarker for Gaucher disease (GD), was shown to contribute to the development or peripheral symptoms in a mouse study, potentially validating its use as a diagnostic tool, according to new research. The study, “Glucosylsphingosine Causes Hematological and Visceral Changes in Mice—Evidence for a Pathophysiological Role in Gaucher Disease,” was published in the International Journal of Molecular Sciences.